Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling Jin GaoHuimin HuXuesong Wang Original Article 18 March 2019 Pages: 1007 - 1015
d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro Henry OppermannMartina MatusovaFrank Gaunitz Original Article 19 March 2019 Pages: 1017 - 1024
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors Niharika B. MettuDonna NiedzwieckiHope Uronis Original Article 20 March 2019 Pages: 1025 - 1035
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer Makoto NatsumeTakaya ShimuraHiromi Kataoka Original Article 21 March 2019 Pages: 1037 - 1046
Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer Takashi KosakaHirotoshi AkiyamaItaru Endo Original Article 25 March 2019 Pages: 1047 - 1055
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma Christophe MassardJean-Charles SoriaHaby Henary Original Article 26 March 2019 Pages: 1057 - 1063
LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma Shian LiaoShuxing XingYanhui Ma Original Article 28 March 2019 Pages: 1065 - 1074
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model Takashi HiguchiKentaro MiyakeRobert M. Hoffman Original Article 30 March 2019 Pages: 1075 - 1082
Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study Hui LiJian ZengWei Hong Original Article 01 April 2019 Pages: 1083 - 1090
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study Murat ArazMustafa KaraagacMehmet Artac Original Article 08 April 2019 Pages: 1091 - 1097
De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer Satoru TanakaNobuki MatsunamiMitsuhiko Iwamoto Original Article 08 April 2019 Pages: 1099 - 1104
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation Sunil AdigeRena G. LapidusAshkan Emadi Original Article 09 April 2019 Pages: 1105 - 1112
Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique Kotaro KimuraKeishi YamasakiMasaki Otagiri Original Article 10 April 2019 Pages: 1113 - 1120
Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study Makoto SakaiMakoto SohdaKen Shirabe Original Article 09 April 2019 Pages: 1121 - 1126
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil Masae SekidoKen-ichi FujitaYasutsuna Sasaki Original Article 09 April 2019 Pages: 1127 - 1135
Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients Derya Kıvrak SalimTuğba Akın TelliPerran Fulden Yumuk Original Article 09 April 2019 Pages: 1137 - 1145
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study Whitney P. KirschbrownMatts KågedalAmit Garg Original Article Open access 11 April 2019 Pages: 1147 - 1158
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents Tim CardilinJoachim AlmquistJohan Gabrielsson Original Article Open access 11 April 2019 Pages: 1159 - 1173
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial Fernando RiveraC. RomeroC. López Clinical Trial Report Open access 29 March 2019 Pages: 1175 - 1181
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer Roger M. PhillipsPaul M. LoadmanGuru Reddy Short Communication Open access 13 March 2019 Pages: 1183 - 1189
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias Muhammad Umer FarooqFahad MushtaqMuhammad Ayaz Mir Short Communication 13 February 2019 Pages: 1191 - 1193
Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability Saadettin KilickapSevgen OnderAysegul Uner Letter to the Editor 12 March 2019 Pages: 1195 - 1196
